macrolid
bacteriostat
antibiot
broad
spectrum
activ
mani
gramposit
atyp
bacteri
speci
commonli
associ
respiratori
tract
infect
min
jang
nih
well
antibacteri
effect
macrolid
shown
immunemodulatori
antiinflammatori
effect
amsden
kanoh
rubin
nakamura
et
al
wale
woodhead
zarogoulidi
et
al
morbid
mortal
caus
respiratori
viral
infect
associ
excess
elabor
cytokin
immunopatholog
host
inflammatori
respons
min
jang
mosquera
et
al
us
wang
et
al
preclin
clinic
studi
shown
macrolid
downregul
inflammatori
respons
attenu
extrem
cytokin
product
promot
induct
immunoglobulin
antibodi
bermejomartin
et
al
may
reduc
complic
respiratori
viral
infect
lee
et
al
lendermon
et
al
min
jang
us
wang
et
al
given
properti
macrolid
eg
azithromycin
clarithromycin
erythromycin
fidaxomicin
telithromycin
studi
potenti
use
target
therapi
wide
spectrum
viral
respiratori
infect
includ
influenza
bermejomartin
et
al
min
jang
suzuki
et
al
tahan
et
al
zhang
et
al
clinic
studi
macrolid
patient
viral
respiratori
infect
yield
contradictori
result
retrospect
analysi
use
clarithromycin
oseltamivir
zanamivir
associ
restor
attenu
antivir
mucos
system
immun
reduct
reinfect
rate
pediatr
patient
influenza
shinahara
et
al
anoth
studi
pediatr
patient
influenzarel
symptom
randomli
assign
group
receiv
either
cephalosporin
macrolid
studi
macrolid
found
effect
allevi
fever
reduc
occurr
pneumonia
ninomiya
et
al
doubleblind
randomis
control
trial
rct
involv
infant
respiratori
syncyti
viru
rsv
relat
bronchiol
administr
clarithromycin
daili
three
week
associ
reduct
hospit
length
stay
lo
supplement
oxygen
need
hospit
readmiss
addit
associ
reduct
plasma
eotaxin
level
tahan
et
al
openlabel
prospect
rct
clarithromycin
associ
fever
reduct
adult
patient
influenza
infect
treat
neuraminidas
inhibitor
howev
differ
reduct
serum
level
studi
group
higashi
et
al
similarli
multicent
openlabel
rct
combin
therapi
osteltamivir
azithromycin
associ
earli
resolut
clinic
symptom
differ
inflammatori
cytokin
level
kakeya
et
al
recent
openlabel
rct
hospit
adult
earli
combin
therapi
clarithromycin
naproxen
oseltamivir
associ
reduc
mortal
hospit
lo
compar
oseltamivir
monotherapi
hung
et
al
similar
result
obtain
secondari
analysi
multicent
rct
use
macrolid
azithromycin
clarithromycin
erythromycin
associ
improv
outcom
includ
mortal
patient
acut
lung
injuri
walkey
wiener
hand
multicent
doubleblind
placebocontrol
equival
rct
use
azithromycin
treat
infant
young
children
rsv
associ
improv
clinic
symptom
kneyber
et
al
similarli
placebocontrol
rct
infant
children
shown
use
azithromycin
bronchiol
reduc
length
stay
oxygen
requir
readmiss
mccallum
et
al
pinto
et
al
one
multicent
observ
studi
macrolid
associ
improv
surviv
critic
ill
patient
primari
viral
pneumonia
martinloech
et
al
patient
middl
east
respiratori
syndrom
mer
macrolid
often
prescrib
part
empir
treatment
regimen
pneumonia
often
detect
mer
coronaviru
merscov
howev
associ
macrolid
mer
outcom
investig
rigor
use
cohort
critic
ill
patient
mer
aim
studi
determin
whether
associ
macrolid
therapi
mortal
macrolid
treatment
merscov
rna
clearanc
respiratori
secret
retrospect
analysi
multicent
cohort
studi
includ
tertiari
care
hospit
five
citi
saudi
arabia
detail
origin
cohort
previous
publish
arabi
et
al
studi
approv
institut
review
board
particip
center
patientlevel
inform
consent
requir
due
observ
natur
studi
includ
patient
admit
particip
hospit
septemb
januari
critic
ill
laboratoryconfirm
mer
retrospect
analysi
patient
divid
one
two
treatment
group
macrolid
therapi
group
patient
receiv
macrolid
treatment
azithromycin
clarithromycin
erythromycin
within
three
day
admiss
icu
time
stay
icu
day
macrolid
therapi
control
group
consist
patient
given
macrolid
timefram
macrolid
typic
administ
part
empir
therapi
pneumonia
although
patient
receiv
erythromycin
gastrointestin
prokinet
agent
standardis
case
report
form
use
data
collect
isar
data
extract
includ
patient
demograph
featur
underli
comorbid
durat
symptom
onset
present
emerg
depart
icu
admiss
intub
sever
patient
ill
assess
use
sequenti
organ
failur
assess
sofa
score
well
laboratori
ventil
paramet
day
icu
admiss
vincent
et
al
result
diagnost
test
document
includ
bacteri
copathogen
atyp
pathogen
includ
legionella
chlamydia
mycoplasma
viral
infect
first
three
day
icu
admiss
detail
antibiot
given
within
first
three
day
icu
admiss
also
document
primari
outcom
allcaus
mortal
also
examin
time
clearanc
merscov
rrtpcr
defin
time
icu
admiss
test
neg
two
occas
without
posit
test
afterward
clearanc
merscov
rrtpcr
calcul
patient
least
one
followup
rrtpcr
test
icu
date
icu
admiss
censor
date
last
test
death
whichev
come
first
compar
baselin
characterist
cointervent
outcom
patient
receiv
macrolid
therapi
categor
variabl
chisquar
test
fisher
exact
test
use
continu
variabl
student
ttest
mannwhitney
u
test
use
appropri
examin
associ
macrolid
therapi
mortal
perform
multivari
logist
regress
analysi
macrolid
therapi
independ
variabl
model
includ
baselin
variabl
clinic
interest
decid
priori
signific
covari
univari
level
p
includ
bodi
mass
index
bmi
sofa
score
admiss
icu
communityacquir
versu
hospitalacquir
infect
healthcar
workerassoci
infect
noninvas
ventil
icu
admiss
malign
chronic
pulmonari
diseas
liver
diseas
sensit
analysi
conduct
exclud
patient
receiv
macrolid
third
day
icu
admiss
examin
associ
macrolid
therapi
merscov
rna
clearanc
use
cox
proport
hazard
model
macrolid
therapi
independ
variabl
includ
model
covari
mention
compet
natur
merscov
rna
clearanc
death
perform
analysi
restrict
survivor
critic
ill
mer
patient
receiv
macrolid
therapi
receiv
azithromycin
figur
time
initi
macrolid
therapi
icu
admiss
among
critic
ill
patient
middl
east
respiratori
syndrom
mer
day
includ
patient
alreadi
macrolid
therapi
admit
icu
patient
reciev
two
macrolid
differ
time
studi
period
one
patient
miss
data
regard
date
macrolid
therapi
receiv
clarithromycin
receiv
erythromycin
patient
receiv
two
macrolid
differ
time
studi
period
patient
receiv
macrolid
alreadi
start
therapi
arriv
icu
start
first
day
icu
figur
demograph
characterist
physiolog
paramet
comorbid
present
symptom
patient
two
studi
group
similar
tabl
supplementari
tabl
howev
patient
macrolid
therapi
group
like
communityacquir
mer
control
group
p
slightli
higher
mean
arteri
pressur
icu
admiss
patient
receiv
macrolid
liver
diseas
slightli
higher
intern
normalis
ratio
inr
read
slightli
higher
bilirubin
level
icu
admiss
signific
differ
group
term
number
day
onset
symptom
emerg
room
present
icu
admiss
intub
tabl
shown
supplementari
tabl
coinfect
respiratori
viru
confirm
patient
patient
macrolid
therapi
group
control
group
atyp
copathogen
diagnos
small
number
patient
legionella
chlamydia
mycoplasma
antibiot
receiv
patient
shown
supplementari
tabl
ny
malign
solid
tumor
leukemia
lymphoma
n
immunosuppress
use
prior
admiss
n
physiolog
paramet
icu
day
sofa
score
median
lascow
coma
score
median
throughout
stay
icu
patient
macrolid
therapi
group
receiv
highfrequ
oscil
ventil
control
group
p
oseltamiv
therapi
versu
p
intraven
immunoglobin
versu
p
renal
replac
therapi
versu
p
tabl
shown
tabl
statist
signific
differ
crude
icu
hospit
mortal
mortal
icu
hospit
lo
macrolid
therapi
group
macrolid
therapi
group
adjust
baselin
variabl
macrolid
therapi
associ
reduct
mortal
compar
macrolid
therapi
group
adjust
ci
p
tabl
sensit
analysi
exclud
patient
receiv
macrolid
day
show
similar
result
adjust
ci
p
cox
proport
hazard
model
reveal
macrolid
therapi
associ
differ
merscov
rna
clearanc
adjust
hr
ci
p
similar
result
reveal
analysi
restrict
survivor
adjust
hr
ci
p
tabl
cohort
studi
found
associ
macrolid
therapi
mortal
merscov
rna
clearanc
among
critic
ill
patient
mer
studi
investig
associ
macrolid
therapi
mortal
patient
influenza
respiratori
viral
infect
hung
et
al
martinloech
et
al
walkey
wiener
howev
result
necessarili
generalis
mer
studi
show
adjust
possibl
confound
use
logist
regress
analysi
macrolid
therapi
associ
signific
chang
mortal
may
suggest
immunomodulatori
effect
macrolid
alon
may
effect
improv
mortal
rate
patient
mer
absenc
effect
antivir
drug
merscov
although
macrolid
known
downregul
inflammatori
respons
reduc
excess
cytokin
secret
associ
respiratori
viral
infect
amsden
beigelman
et
al
kanoh
rubin
lendermon
et
al
zarogoulidi
et
al
direct
effect
viral
clearanc
patient
respiratori
viral
infect
uncertain
vitro
studi
human
bronchial
epitheli
cell
show
azithromycin
significantli
reduc
rhinoviru
replic
releas
gielen
et
al
schogler
et
al
howev
anoth
studi
report
azithromycin
directli
alter
viral
replic
clearanc
parainfluenza
type
sendai
viru
mice
beigelman
et
al
similarli
rct
azithromycin
therapi
infant
sever
rsv
bronchiol
facilit
rsv
clearanc
upper
airway
compar
placebo
beigelman
et
al
rct
adult
hospit
laboratori
confirm
influenza
random
receiv
oseltamivir
azithromycin
oseltamivir
alon
day
lee
et
al
proinflammatori
cytokin
declin
faster
oseltamivirazithromycin
group
howev
viral
rna
declin
affect
lee
et
al
studi
first
investig
associ
macrolid
therapi
merscov
rna
clearanc
result
show
macrolid
therapi
signific
associ
previou
studi
demonstr
improv
symptom
respiratori
virus
includ
influenza
patient
treat
macrolid
ninomiya
et
al
tahan
et
al
higashi
et
al
kakeya
et
al
due
natur
popul
studi
critic
ill
patient
studi
measur
differ
symptom
improv
group
receiv
macrolid
group
receiv
macrolid
measur
potenti
improv
merscov
symptom
macrolid
therapi
may
consid
futur
studi
result
interpret
light
strength
weak
studi
first
examin
use
macrolid
therapi
patient
merscov
deriv
collabor
multicent
observ
databas
critic
ill
patient
merscov
enhanc
generaliz
find
mitig
possibl
centrerel
effect
studi
also
use
intern
standardis
data
collect
tool
adjust
possibl
confound
includ
communityacquir
infect
probabl
associ
variabl
exposur
macrolid
therapi
outcom
sinc
macrolid
therapi
initi
earli
icu
cours
risk
immort
time
bia
survivorship
bia
probabl
limit
main
limit
retrospect
natur
observ
studi
potenti
unmeasur
confound
may
influenc
relationship
sought
examin
also
measur
cytokin
level
immun
measur
might
affect
macrolid
administr
studi
onethird
critic
ill
patient
merscov
receiv
empir
therapi
macrolid
howev
found
macrolid
therapi
significantli
associ
reduct
mortal
improv
merscov
rna
clearanc
